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CD11b/CD18 Mediates Production of Reactive Oxygen
Species by Mouse and Human Macrophages Adherent to
Matrixes Containing Oxidized LDL
Jens Husemann, Amrom Obstfeld, Maria Febbraio, Tatsuhiko Kodama, Samuel C. Silverstein
Abstract—Production of reactive oxygen species (ROS) and other proinflammatory substances by macrophages adherent
to matrix proteins that contain or have been modified by oxidized LDL (oxLDL) may play an important role in
atherogenesis. In vitro, human macrophages adhere to matrixes containing oxLDL via scavenger receptors and are
signaled to produce ROS partly by interactions of the class B scavenger receptor (SR-B) CD36 with ligands on the
matrix. In this report, we show that macrophages from mice genetically deficient in SR-A or CD36 adhered equally as
well and produced equal amounts of ROS on interaction with matrix-associated oxLDL. In contrast, macrophages from
mice genetically deficient in the CD18 chain of b2-integrins produced insignificant amounts of ROS on interaction with
oxLDL-containing matrixes, even though they adhered to these matrixes as efficiently as did macrophages from
wild-type mice. Antibodies against CD18, CD11b, or EDTA, the last of which chelates divalent cations required for
integrin function, had no effect on adhesion of normal mouse or human macrophages to matrixes containing oxLDL but
almost completely inhibited ROS production by macrophages adherent to this matrix. Thus, CD11b/CD18 plays an
important role in regulating production of ROS by mouse and human macrophages adherent to matrixes containing
oxLDL. It may play a hitherto-unsuspected role in regulating macrophage signaling pathways involved in inflammation
and atherogenesis. (Arterioscler Thromb Vasc Biol. 2001;21:1301-1305.)
Key Words: reactive oxygen species n macrophages n oxidized LDL n CD11b/CD18 n scavenger receptors
Accumulation of oxidatively modified LDL (oxLDL) inand subsequent recruitment of monocytes to the suben-
dothelial space of arteries are early events in atherogenesis
(reviewed in Lusis1). Monocytes trapped at this site via
interactions of their scavenger receptors (eg, SR-A, CD36)
with oxLDL and with matrix proteins modified by oxidized
lipids mature into macrophages. Endocytosis of modified
lipids and lipoproteins by these macrophages transforms them
into foam cells. Foam cells form fatty streaks, which contrib-
ute to the development of atherosclerotic lesions.
Like macrophages, endothelial cells (ECs) and smooth
muscle cells (SMCs) express scavenger-type receptors that
interact with ligands expressed on oxLDL and on matrix
proteins modified by oxidized lipids.1 These interactions
stimulate macrophages, vascular SMCs, and vascular ECs to
produce reactive oxygen species (ROS),1 eg, superoxide,
which spontaneously reacts with water to generate other
ROS, eg, H2O2. These ROS cause further oxidative modifi-
cation of lipids and lipoproteins. Macrophages are thought to
play the most prominent role in these processes owing to their
high levels of ROS-generating enzymes, eg, NADPH oxidase
and 5/12-lipoxygenase.1 We have reported that although
SR-A plays a major role in promoting adhesion of human
macrophages to oxLDL-containing matrixes, it appears to
play little or no role in signaling ROS production.2 In
contrast, antibodies that block interactions of the class B
scavenger receptor CD36 with oxLDL have no effect on
macrophage adhesion to oxLDL-containing matrixes but do
inhibit ROS production by human macrophages adherent to
these matrixes by ’60%.2 To further explore these findings,
we compared adhesion to and ROS production by resident
peritoneal macrophages from mice genetically deficient in
SR-A (SR-A2/2), CD36 (CD362/2), or CD18 (CD182/2)
plated on oxLDL-containing matrixes with that of macro-
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All reagents were from Sigma Chemical Co unless indicated
otherwise.
Mice
All mice used in these experiments were 6 to 8 weeks of age.
SR-A2/2,3 CD362/2,4 and CD182/25 mice are described elsewhere.
Cells
Mouse mononuclear cells were obtained by lavage of the peritoneal
cavity and used in experiments immediately thereafter.6 Twenty-nine
percent (63%) of the cells harvested from the peritoneum of
knockout mice and background-appropriate wild-type mice were
macrophages, as indicated by their expression of nonspecific esterase
and endocytosis of 1,19-dioctadecyl-3,3,39,39-tetramethylin-
docarbocyanine perchlorate–labeled acetylated LDL (not shown).7
Human monocytes were isolated from fresh buffy coats (New York
Blood Center, New York, NY) and cultured for 3 to 5 days as
described before being used in experiments.2
Adhesion
To compare adhesion of wild-type, SR-A2/2, CD362/2, and CD182/2
mouse peritoneal mononuclear cells, we used surfaces coated with
collagen IV alone (CIV), collagen IV and native LDL (CIV/LDL), or
collagen IV and oxLDL (CIV/oxLDL). Because macrophages do not
adhere efficiently to collagen IV,7 surfaces coated with this protein
facilitate detection of adhesion-promoting ligands, such as oxLDL,
absorbed to it.
To measure adhesion, 6-mm-diameter spots of multispot slides
were incubated with 30 mL per spot of 50 mg/mL collagen IV (Fluka)
in double-distilled water for 1 hour at 37°C, washed once with
double-distilled water, air-dried, coated with 10 mg LDL per spot
(Intracell) or oxLDL as described,2 air-dried again, and overlaid with
50 mL Krebs-Ringer buffer containing 1 mmol/L glucose (Sigma)
and 0.1% bovine serum albumin (Sigma) (KRBGA solution) con-
taining 2.53104 mouse peritoneal mononuclear cells or human
macrophages for 45 minutes at 37°C in a 5% CO2/95% air atmo-
sphere. Slides were washed with KRBGA, and the number of
adherent cells was determined by using CyQuant GR cell prolifera-
tion assay (Molecular Probes) according to the manufacturer’s
instructions.
ROS Production
Accumulation of H2O2 as a representative ROS in the supernatant
was measured with the Amplex Red™ H2O2 assay (Molecular
Probes) according to the manufacturer’s instructions. The wells of
96-well, flat-bottomed microtiter plates were coated with CIV,
CIV/LDL, or CIV/oxLDL as described above and overlaid with 150
mL KRBGA containing 20 mmmol/L Amplex Red™ (Molecular
Probes), 0.2 U/mL horseradish peroxidase (Molecular Probes), and
33105 mouse peritoneal mononuclear cells or human macrophages
for 2 hours at 37°C in a 5% CO2/95% air atmosphere. Fluorescence
of the product formed by the reaction between Amplex Red™ and
H2O2 was assayed with a fluorescent plate reader.
Antibodies
Mouse peritoneal mononuclear cells or human macrophages were
preincubated with KRBGA containing monoclonal rat anti-mouse
CD18 IgG1;k (Pharmingen) or control rat IgG1;k (Pharmingen) at 0.4,
2, or 10 mg/mL; monoclonal mouse anti-human CD18 IgG1b (Ancell
Corp) or control mouse IgG1b (AnCell) at 0.4, 2, or 10 mg/mL; or
monoclonal rat anti-mouse/human CD11b IgG2b (Serotec) or control
rat IgG2b (Pharmingen) at 0.04, 0.2, or 1 mg/mL for 15 minutes at
37°C in a 5% CO2/95% air atmosphere where indicated.
Statistical Analysis
All experiments were performed with triplicate samples for 3 lots of
macrophages. Student’s t test was used to pairwise compare adhesion
(Figures 1 and 3b) and accumulation of H2O2 (Figures 2 and 3a) by
wild-type mouse macrophages plated on CIV/oxLDL with wild-type
macrophages plated on CIV or CIV/LDL, or by knockout macro-
phages (SR-A2/2, CD362/2, or CD182/2) plated on CIV/oxLDL.
Student’s t test was used to compare adhesion (not shown) and
accumulation of H2O2 (Figure 3c) by human or wild-type mouse
macrophages plated on CIV/oxLDL in the absence of antibody or
EDTA (leftmost cluster of bars) with macrophages preincubated with
anti-CD11b, anti-CD18, control antibodies (not shown), or EDTA.
Data are presented as mean6SEM, with ** indicating P#0.01.
Results
Less than 4% of total mononuclear cells (’13% of macro-
phages) from wild-type mice, SR-A2/2 mice, and CD362/2
mice adhered to surfaces coated with CIV or CIV/LDL
(Figure 1), whereas ’23% of total mononuclear cells (’78%
of macrophages) from wild-type, SR-A2/2, and CD362/2 mice
adhered to surfaces coated with CIV/oxLDL (Figure 1).
These findings indicate that neither SR-A nor CD36 is
required for adhesion of murine peritoneal macrophages to
oxLDL-containing matrixes and that other adhesion-
Figure 1. Adhesion of peritoneal macrophages from knockout
mice (gray bars) lacking SR-A (SR-A2/2) or CD36 (CD362/2) and
background-appropriate wild-type mice (black bars) to surfaces
coated with CIV, CIV/LDL, or CIV/oxLDL.
Figure 2. Accumulation of H2O2 in the supernatant on plating of
peritoneal macrophages from knockout mice (gray bars) lacking
SR-A (SR-A2/2) or CD36 (CD362/2) and background-appropriate
wild-type mice (black bars) on surfaces coated with CIV, CIV/
LDL, or CIV/oxLDL.
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mediating receptors, eg SR-BI,7 may mediate macrophage
binding to ligands provided by oxLDL.
To assess whether adhesion to CIV, CIV/LDL, or CIV/
oxLDL stimulates ROS production by SR-A2/2, CD362/2, or
wild-type murine macrophages, we incubated these cells on
matrixes containing these proteins and assayed for accumu-
lation of H2O2 in the supernatant as a representative ROS.
Consistent with the findings of Maxeiner et al,2 wild-type
mouse peritoneal macrophages produced very little ROS on
surfaces coated with CIV or CIV/LDL (’33 pmol H2O2 per
33105 cells/2 hours; Figure 2) but produced significantly
more ROS on surfaces coated with CIV/oxLDL (’185 pmol
H2O2 per 33105 cells/2 hours; Figure 2). However, in contrast
to the results predicted by Maxeiner et al,2 macrophages from
SR-A2/2 and CD362/2 mice produced at least as much ROS as
did wild-type macrophages (’247636 and ’188647 pmol
H2O2 per 33105 cells/2 hours, respectively; Figure 2). These
findings show that receptors other than SR-A and CD36 can
mediate adhesion of resident macrophages to oxLDL-
containing matrixes and ROS production by these cells when
they adhere to such matrixes.
Interestingly, neutrophils also have been shown to produce
ROS on interaction with oxLDL (see Maeba et al8 and J.H.,
unpublished observations, 2000). Neutrophils are not found
in atherosclerotic lesions and do not express detectable levels
of SR-A or CD36 (Naito et al9 and J.H., unpublished
observations, 2000) but do express high levels of the b2-
integrin CD11b/CD18 (also known as Mac-1, complement
receptor 3, CR3). Neutrophils and macrophages can be
induced to produce ROS when they adhere to surfaces
containing ligands for CD11b/CD18 (eg, fibrinogen, iC3b10).
This suggested a role for CD11b/CD18 in ROS production by
macrophages. As anticipated, resident peritoneal macro-
phages from mice genetically deficient in the b2-chain of
CD11b/CD18 (CD182/2 mice) adhered as efficiently to ma-
trixes containing CIV/oxLDL as did wild-type murine mac-
rophages (Figure 3b). However, macrophages from CD182/2
mice produced ’20% as much ROS as did wild-type mac-
rophages on adhesion to this matrix (Figure 3a). The amount
of ROS produced by CD182/2 macrophages adherent to
CIV/oxLDL (’39 pmol H2O2 per 33105 cells/2 hours; Figure
3a) was not significantly different from the amount secreted
by wild-type macrophages adherent to surfaces containing
CIV or CIV/LDL (’33 pmol H2O2 per 33105 cells/2 hours;
Figure 1). These results indicate that CD18 plays a hitherto-
unanticipated role in oxLDL-stimulated ROS production by
macrophages.
To further explore this finding, we assessed the effect of
antibodies against mouse and human CD18 or CD11b on
ROS production by mouse and human macrophages adherent
to surfaces containing CIV/oxLDL. These antibodies almost
completely inhibited ROS production by mouse or human
macrophages. Neither anti-CD18 nor anti-CD11b IgG had
any effect on adhesion of these cells to surfaces containing
CIV/oxLDL (not shown). The same concentration of isotype-
matched control IgG had no effect on mouse or human
macrophage adhesion to or ROS production on CIV/oxLDL
(not shown).
b2-Integrins require divalent cations to bind ligands. To
determine whether the divalent cation–dependent, ligand-
binding domain of CD11b/CD18 is involved in this system,
we tested the effect of 5 mmol/L EDTA on adhesion and ROS
production by mouse and human macrophages plated on
CIV/oxLDL. EDTA had no effect on macrophage adhesion
but caused an ’80% decrease in ROS production by wild-
type mouse and human macrophages plated on CIV/oxLDL
(Figure 3c). To confirm that EDTA did not block ROS
production per se, we tested ROS production by resident
mouse peritoneal macrophages and by human blood mono-
cyte–derived macrophages stimulated with 100 ng/mL phor-
bol myristate acetate or 10 mg/mL zymosan. The presence of
EDTA had no effect on ROS production induced by these
stimuli (data not shown).
Thus, by genetically eliminating expression of CD18, use
of antibodies that masked the ligand-binding domain(s) of
CD18, and chelation of divalent cations required for CD11/
CD18 functions, we have disrupted a required step in ROS
production by macrophages adherent to oxLDL-containing
matrixes. Because antibodies against CD11b/CD18 are as
effective in inhibiting ROS production as is the absence of all
4 b2-integrins in CD182/2 macrophages, it appears that
CD11b/CD18 is the b2-integrin involved in this signaling
pathway.
Discussion
To enter the subendothelial space, blood monocytes must
cross the vascular endothelium. Leukocyte and endothelial
cell adhesion molecules such as intercellular adhesion
molecule-1, vascular cell adhesion molecule-1 (VCAM-1),
very late–acting antigen-4 (VLA-4), P-selectin, L-selectin,
and CD18, along with chemoattractants such as monocyte
Figure 3. a, Accumulation of H2O2 in the super-
natant on plating of peritoneal macrophages
from knockout mice (gray bar) lacking CD18
(CD182/2) and background-appropriate wild-
type mice (black bar) on surfaces coated with
CIV/oxLDL. b, Adhesion of peritoneal macro-
phages from knockout mice (gray bar) lacking
CD18 (CD182/2) and background-appropriate
wild-type mice (black bar) to CIV/oxLDL. c,
Effect of anti-CD11b and anti-CD18 IgG and of
EDTA on accumulation of H2O2 in the superna-
tant on plating of mouse (black bars) or human
(gray bars) macrophages on surfaces coated
with CIV/oxLDL compared with macrophages
plated on this surface in the absence of anti-
bodies or EDTA (control).
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chemotactic protein-1 (MCP-1), are involved in this process
to differing degrees, depending on the circumstances. Genetic
disruption of intercellular adhesion molecule-1,11
P-selectin,11 or MCP-112 of endothelial cells or of CD1811 or
CCR2, the receptor for MCP-1 on macrophages,13 does not
affect plasma lipids but results in decreased macrophage
numbers in fatty streaks and reduced lesion size in murine
models of atherosclerosis. These results indicate that mono-
cyte recruitment plays an important role in the initiation of
atherosclerosis. There are insufficient data to determine
whether such a decrease in monocyte recruitment and lesion
size would translate into reduced long-term morbidity and
mortality in atherosclerosis in humans.
Monocytes that enter the subendothelial space mature into
macrophages that interact with and ingest oxLDL via scav-
enger receptors (eg, SR-A, SR-BI, CD36), thereby becoming
foam cells.1 Interactions with matrix-bound oxLDL may also
stimulate these macrophages to produce ROS in vivo, as they
do in vitro (eg, Figures 1 through 3 and References 2 and 14).
The NADPH oxidase and the 12/15-lipoxygenase pathways
are thought to play important roles in the atherogenic effects
of macrophages. NADPH oxidase is upregulated in macro-
phages in atherosclerotic lesions.15 Inhibitors of NADPH
oxidase slow the appearance of vascular lesions in a rabbit
model of atherosclerosis.16 In mouse models, however, ge-
netic disruption of 2 subunits of NADPH oxidase (gp91phox17
and p47phox18) had no significant effect on lesion development.
There are no reports of atherosclerosis in patients whose
monocytes are deficient in NADPH oxidase (eg, chronic
granulomatous disease). Macrophages from such patients
retain the ability to produce ROS through the 15-lipoxygen-
ase pathway,19,20 especially after treatment with cytokines21
(eg, g-interferon22). Furthermore, chronic granulomatous dis-
ease macrophages oxidize LDL in vitro, though with reduced
efficiency.14
15-Lipoxygenase colocalizes with epitopes of oxLDL in
human and rabbit atherosclerotic lesions.23 Genetic disruption
of 12/15-lipoxygenases in a mouse model of atherosclerosis24
or inhibition of 15-lipoxygenase in a rabbit model25 of
atherosclerosis has been reported to limit the progression of
atherosclerotic lesions. These results suggest that macrophage
production of ROS via both the NADPH and lipoxygenase
pathways contributes to the development of atherosclerosis.
The finding that the absence or inhibition of CD11b/CD18
reduces ROS production by macrophages adherent to a
matrix containing oxLDL by ’80% suggests that CD11b/
CD18 plays a role in atherosclerosis. Nageh et al11 observed
an ’50% reduction in fatty streaks in mice whose CD18
genes had been knocked out.
Anti-CD18 antibodies reduce migration of monocytes
across unstimulated human umbilical vein EC monolayers by
’75%.26 However, when human umbilical vein EC mono-
layers are pretreated with proinflammatory substances (eg,
lipopolysaccharide, tumor necrosis factor-a, or interleukin-
1b), migration is no longer inhibited by anti-CD18 antibodies
but is blocked by antibodies against VLA-4 and VCAM-1.26
This suggests that monocyte migration across “inflamed”
endothelium is CD18 independent. The findings reported here
raise the possibility that the reduction in atherosclerotic lesion
size observed by Nageh et al11 may reflect decreased produc-
tion of ROS and other proinflammatory substances within the
subendothelial compartment rather than reduced monocyte
migration across the vascular endothelium into this
compartment.
The mechanism by which CD11b/CD18 participates in
ROS production by neutrophils and macrophages remains
unresolved. At present, there is no evidence that CD11b/
CD18 interacts directly with oxLDL. As documented here,
b2-integrins are not required for adhesion to oxLDL-
containing matrixes (Figure 3b). It is possible that activation
of CD11b/CD18 by signals generated by the interactions of
specific cell surface receptors with matrix-bound oxLDL
capacitates this receptor to organize/assemble the NADPH
oxidase. Whatever mechanism is responsible, the findings
reported here indicate a central and hitherto-unsuspected role
for CD18 in regulating oxidant production by macrophages in
atherosclerotic lesions.
In conclusion, CD11b/CD18 may be a significant player in
regulating macrophage signaling pathways involved in
atherogenesis. In humans, CD11b/CD18 may cooperate with
CD36 in signaling ROS production on macrophage interac-
tion with oxLDL.2 In macrophages from CD362/2 mice,
however, CD36 is not required for this response (Figure 2).
ROS and possibly other proinflammatory substances (eg,
nitric oxide) produced by macrophages interacting with
oxLDL may contribute to the initiation and/or progression of
vascular disease by oxidizing extracellular matrix proteins,
lipoproteins, and lipids and stimulating cell death. Inhibition
of ROS or nitric oxide production27 has been demonstrated to
slow progression of atherosclerosis. The findings reported
here raise the possibility that agents that disrupt the partici-
pation of CD11b/CD18 in intracellular signaling pathways
could slow the onset and/or progression of atherosclerosis
and other diseases involving macrophage ROS production.
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